TWI799855B - 抗新型冠狀病毒(SARS-CoV-2)之新穎單株抗體及其應用 - Google Patents

抗新型冠狀病毒(SARS-CoV-2)之新穎單株抗體及其應用 Download PDF

Info

Publication number
TWI799855B
TWI799855B TW110116981A TW110116981A TWI799855B TW I799855 B TWI799855 B TW I799855B TW 110116981 A TW110116981 A TW 110116981A TW 110116981 A TW110116981 A TW 110116981A TW I799855 B TWI799855 B TW I799855B
Authority
TW
Taiwan
Prior art keywords
cov
monoclonal antibodies
antibodies against
novel monoclonal
against sars
Prior art date
Application number
TW110116981A
Other languages
English (en)
Other versions
TW202144405A (zh
Inventor
黃冠穎
Original Assignee
長庚醫療財團法人林口長庚紀念醫院
高端疫苗生物製劑股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 長庚醫療財團法人林口長庚紀念醫院, 高端疫苗生物製劑股份有限公司 filed Critical 長庚醫療財團法人林口長庚紀念醫院
Publication of TW202144405A publication Critical patent/TW202144405A/zh
Application granted granted Critical
Publication of TWI799855B publication Critical patent/TWI799855B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1002—Coronaviridae
    • C07K16/1003—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2 or Covid-19]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54366—Apparatus specially adapted for solid-phase testing
    • G01N33/54386—Analytical elements
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/10—Detection of antigens from microorganism in sample from host
TW110116981A 2020-05-11 2021-05-11 抗新型冠狀病毒(SARS-CoV-2)之新穎單株抗體及其應用 TWI799855B (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US202063022844P 2020-05-11 2020-05-11
US63/022,844 2020-05-11
US202063029980P 2020-05-26 2020-05-26
US63/029,980 2020-05-26
US202063070560P 2020-08-26 2020-08-26
US63/070,560 2020-08-26

Publications (2)

Publication Number Publication Date
TW202144405A TW202144405A (zh) 2021-12-01
TWI799855B true TWI799855B (zh) 2023-04-21

Family

ID=78525291

Family Applications (1)

Application Number Title Priority Date Filing Date
TW110116981A TWI799855B (zh) 2020-05-11 2021-05-11 抗新型冠狀病毒(SARS-CoV-2)之新穎單株抗體及其應用

Country Status (4)

Country Link
US (1) US20230279079A1 (zh)
AU (1) AU2021271388A1 (zh)
TW (1) TWI799855B (zh)
WO (1) WO2021228092A1 (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114031685B (zh) * 2022-01-10 2022-03-25 中国人民解放军军事科学院军事医学研究院 一种全人源抗新冠病毒中和抗体zw2g10及应用
CN114703147A (zh) * 2022-04-18 2022-07-05 扬州大学 一种抗SARS-CoV-2广谱中和性单克隆抗体及其杂交瘤细胞株、检测试剂盒和应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110974950B (zh) * 2020-03-05 2020-08-07 广州恩宝生物医药科技有限公司 一种用于预防SARS-CoV-2感染的腺病毒载体疫苗
CN111088283B (zh) * 2020-03-20 2020-06-23 苏州奥特铭医药科技有限公司 mVSV病毒载体及其病毒载体疫苗、一种基于mVSV介导的新冠肺炎疫苗

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
期刊 Wang C., et al., "A human monoclonal antibody blocking SARS-CoV-2 infection", Nature communications, Vol. 11:2251 2020 (Published online: 04 May 2020), https://doi.org/10.1038/s41467-020-16256-y.

Also Published As

Publication number Publication date
TW202144405A (zh) 2021-12-01
AU2021271388A1 (en) 2022-12-15
US20230279079A1 (en) 2023-09-07
WO2021228092A1 (en) 2021-11-18

Similar Documents

Publication Publication Date Title
EP4010378A4 (en) ANTICCR8 MONOCLONAL ANTIBODIES AND USES THEREOF
EP3901175A4 (en) ANTI-CD73 MONOCLONAL ANTIBODY AND USE THEREOF
EP4008730A4 (en) BISPECIFIC ANTI-CTLA4-ANTI-PD-1 ANTIBODY AND ITS USES
EP3918323A4 (en) ANTI-GAL3 ANTIBODIES AND THEIR USES
EP3997127A4 (en) ANTIBODIES TARGETING DLL3 AND THEIR USES
EP3988574A4 (en) AGAINST HER2 BI-SPECIFIC ANTIBODIES AND THEIR USE
EP3999545A4 (en) ANTI-CD73 ANTIBODIES AND USE THEREOF
EP3990498A4 (en) ANTI-CD24 ANTIBODIES AND USES THEREOF
EP3919512A4 (en) HUMANIZED ANTI-Abeta MONOCLONAL ANTIBODY AND USE
EP4039708A4 (en) ANTI-CLL1 ANTIBODIES AND ITS USE
EP3962954A4 (en) ANTI-GALECTIN-9 ANTIBODIES AND THEIR USES
EP3992211A4 (en) ANTI-CEA ANTIBODIES AND ITS USE
EP3966252A4 (en) HUMANIZED ANTI-CD137 ANTIBODIES AND THEIR USES
TWI799855B (zh) 抗新型冠狀病毒(SARS-CoV-2)之新穎單株抗體及其應用
EP4001308A4 (en) ANTI-TIGIT ANTIBODIES AND THEIR APPLICATION
EP4071172A4 (en) ANTI-LILRB1 ANTIBODIES AND ITS USES
EP4025609A4 (en) ANTI-STEAP1 ANTIBODIES AND USES THEREOF
EP3981793A4 (en) CEACAM5-RESISTANT MONOCLONAL ANTIBODY AND METHODS FOR ITS PRODUCTION AND ITS USE
EP4010368A4 (en) ANTI-NAMPT ANTIBODIES AND THEIR USES
EP4036113A4 (en) HUMANIZED ANTI-IL17A ANTIBODY AND USE THEREOF
EP3947462A4 (en) ANTI-GALECTIN-9 ANTIBODIES AND USES THEREOF
AU2022298850A1 (en) Anti-ccr8 antibodies and uses thereof
EP4274851A4 (en) MONOCLONAL ANTI-GPRC5D ANTIBODIES AND USES THEREOF
EP4025611A4 (en) ANTI-CXCR2 ANTIBODIES AND THEIR USES
EP3976659A4 (en) ANTI-GLYPICAN-3 ANTIBODIES AND USES THEREOF